| University of Arizona College of Pharmacy Medication Therapy Management |
Cooperative Agreement |
119,192.00 |
Other Sponsored Activity |
David Axon |
Pharmacy Practice and Science |
06/2024 |
| VA IPA for Bret Tallent (VA PI: Jonathan Lifshitz) |
Contract |
121,166.00 |
Research |
Jonathan Lifshitz |
COM Phx Psychiatry |
06/2024 |
| Visualization of the STN and GPi for DBS Surgery in Patients with Parkinson's Disease: VISION Study |
Contract |
117,316.00 |
Clinical Trial |
Julie Pilitsis |
Neurosurgery |
06/2024 |
| Wassaja Website Build - PYT Gaming |
Grant |
25,000.00 |
Other Sponsored Activity |
Christina Andrews |
Family and Community Medicine |
06/2024 |
| ZerO Degree Head Positioning In Acute IschemiC Stroke (ZODIAC) |
Grant |
26,457.00 |
Research |
Peter Nakaji |
COM Phx Neurology |
06/2024 |
| A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent And Combination Therapy In Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors |
Contract |
1,631,033.00 |
Clinical Trial |
Aaron Scott |
Cancer Center Division |
05/2024 |
| A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG) in Patients with Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma |
Contract |
625,394.00 |
Clinical Trial |
Edward Gelmann |
Cancer Center Division |
05/2024 |
| A Phase 2a Single-Arm, Open-Label, Exploratory Study to Assess the Effects of LAM-001 (Inhaled Sirolimus) for the Treatment of Pulmonary Hypertension |
Contract |
261,336.60 |
Clinical Trial |
Franz Rischard |
Medicine |
05/2024 |
| A Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Biomarkers with Oral Colon Delivery |
Contract |
2,600.00 |
Clinical Trial |
Sasha Taleban |
Medicine |
05/2024 |
| A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ul |
Contract |
2,600.00 |
Clinical Trial |
Sasha Taleban |
Medicine |
05/2024 |
| A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator's Choice in Previously Untreated |
Contract |
7,464,772.60 |
Clinical Trial |
Abhijeet Kumar |
Cancer Center Division |
05/2024 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) |
Contract |
277,295.00 |
Clinical Trial |
Chian Kwoh |
Arthritis Center-Research |
05/2024 |
| APOE Regulation of Neuron-Astrocyte Metabolic Coupling in Alzheimer's Disease |
Grant |
758,159.00 |
Research |
Fei Yin |
UAHS Brain Science |
05/2024 |
| Behavioral Sleep Medicine: Training in Sleep and Aging |
Grant |
19,980.00 |
Instruction |
Michael Grandner |
Psychiatry |
05/2024 |
| Biological Function and Regulation of PRMT9 in Synapse Development |
Grant |
128,937.00 |
Research |
Shenfeng Qiu |
COM Phx Basic Medical Sci |
05/2024 |
| CNIC Research Collaboration |
Contract |
396,000.00 |
Research |
HESHAM SADEK |
Sarver Heart Center |
05/2024 |
| COG Amazon Supplemental Payments |
Cooperative Agreement |
100,000.00 |
Clinical Trial |
Holly Pariury |
Cancer Center Division |
05/2024 |
| COG Per-case Reimbursement St. Baldrick's Supplement |
Cooperative Agreement |
100,000.00 |
Clinical Trial |
Holly Pariury |
Cancer Center Division |
05/2024 |
| COG Project: Everychild (Apec14b1) Supplemental Per-case Reimbursement |
Cooperative Agreement |
100,000.00 |
Clinical Trial |
Holly Pariury |
Cancer Center Division |
05/2024 |
| Cytoskeletal Regulation of Lung Endothelial Pathobiology in ARDS |
Grant |
1,454,288.00 |
Research |
Anne Cress |
Cellular & Molecular Medicine |
05/2024 |
